Taking a special combo pill (niacin + laropiprant) along with your statin for heart disease might make your cholesterol numbers look better, but it also causes more dangerous side effects — so overall, it does more harm than good.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
This claim is based on high-quality randomized controlled trials (e.g., HPS2-THRIVE) that directly tested the intervention and measured hard clinical outcomes (serious adverse events and lipid changes). The conclusion reflects a consistent, replicated finding across large-scale studies with low risk of bias. The use of 'increases' and 'net unfavorable' is justified by statistically significant harm outweighing modest lipid benefits. No overstatement is present.
More Accurate Statement
“In adults with atherosclerotic vascular disease on statin therapy, the addition of extended-release niacin with laropiprant increases the overall risk of serious adverse events and results in a net unfavorable risk-benefit profile, despite modest improvements in lipid levels.”
Context Details
Domain
medicine
Population
human
Subject
Adults with atherosclerotic vascular disease on statin therapy
Action
increases the risk of serious adverse events overall, despite improving lipid levels, leading to a net unfavorable risk-benefit profile
Target
Extended-release niacin with laropiprant
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Effects of extended-release niacin with laropiprant in high-risk patients.
This study gave people with heart disease niacin and laropiprant along with their statin pills. Even though their cholesterol numbers got better, they had more serious health problems like diabetes flare-ups and infections — and didn’t have fewer heart attacks or strokes. So, the upsides didn’t outweigh the downsides.